The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.